Lack of association of induration size with HIV infection among drug users reacting to tuberculin

Marc N. Gourevitch, Diana Hartel, Ellie Schoenbaum, Robert S. Klein

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Smaller tuberculin test induration sizes suggest eligibility for tuberculosis chemoprophylaxis in HIV-seropositive than in HIV-seronegative persons. To determine whether human immunodeficiency virus (HIV) infection is associated with induration size among tuberculin reactors, a cross-sectional study of HIV-seropositive and -seronegative drug users was performed. Twenty- four of 160 (15%) HIV-seropositive and 68 of 284 (24%) HIV-seronegative patients had reactions to purified protein derivative (PPD) of ≤ 2 mm (OR = 0.56, 95% CI 0.32 to 0.96). However, the prevalence of tuberculin reactivity was equal among nonanergic subjects with and without HIV infection. Median induration size was similar among HIV-seropositive (20.5 mm) and - seronegative (17.5 mm) reactors. Thus, although HIV-seropositive patients were less likely, due to cutaneous anergy, to be PPD reactors, induration size was not associated with HIV infection among reactors. Although using a reduced cutpoint to determine suitability of chemoprophylaxis in HIV- seropositive persons may be prudent, the logical assumption that the loss of specificity this entails is accompanied by an increase in sensitivity for detecting Mycobacterium tuberculosis infection remains to be proved.

Original languageEnglish (US)
Pages (from-to)1029-1033
Number of pages5
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume154
Issue number4 I
StatePublished - 1996

Fingerprint

Tuberculin
Virus Diseases
Drug Users
HIV
Chemoprevention
Tuberculin Test
Mycobacterium Infections
Mycobacterium tuberculosis
Tuberculosis
Proteins
Cross-Sectional Studies
Skin

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Lack of association of induration size with HIV infection among drug users reacting to tuberculin. / Gourevitch, Marc N.; Hartel, Diana; Schoenbaum, Ellie; Klein, Robert S.

In: American Journal of Respiratory and Critical Care Medicine, Vol. 154, No. 4 I, 1996, p. 1029-1033.

Research output: Contribution to journalArticle

@article{35ba45bd8fe94c82b19395ec70939437,
title = "Lack of association of induration size with HIV infection among drug users reacting to tuberculin",
abstract = "Smaller tuberculin test induration sizes suggest eligibility for tuberculosis chemoprophylaxis in HIV-seropositive than in HIV-seronegative persons. To determine whether human immunodeficiency virus (HIV) infection is associated with induration size among tuberculin reactors, a cross-sectional study of HIV-seropositive and -seronegative drug users was performed. Twenty- four of 160 (15{\%}) HIV-seropositive and 68 of 284 (24{\%}) HIV-seronegative patients had reactions to purified protein derivative (PPD) of ≤ 2 mm (OR = 0.56, 95{\%} CI 0.32 to 0.96). However, the prevalence of tuberculin reactivity was equal among nonanergic subjects with and without HIV infection. Median induration size was similar among HIV-seropositive (20.5 mm) and - seronegative (17.5 mm) reactors. Thus, although HIV-seropositive patients were less likely, due to cutaneous anergy, to be PPD reactors, induration size was not associated with HIV infection among reactors. Although using a reduced cutpoint to determine suitability of chemoprophylaxis in HIV- seropositive persons may be prudent, the logical assumption that the loss of specificity this entails is accompanied by an increase in sensitivity for detecting Mycobacterium tuberculosis infection remains to be proved.",
author = "Gourevitch, {Marc N.} and Diana Hartel and Ellie Schoenbaum and Klein, {Robert S.}",
year = "1996",
language = "English (US)",
volume = "154",
pages = "1029--1033",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "4 I",

}

TY - JOUR

T1 - Lack of association of induration size with HIV infection among drug users reacting to tuberculin

AU - Gourevitch, Marc N.

AU - Hartel, Diana

AU - Schoenbaum, Ellie

AU - Klein, Robert S.

PY - 1996

Y1 - 1996

N2 - Smaller tuberculin test induration sizes suggest eligibility for tuberculosis chemoprophylaxis in HIV-seropositive than in HIV-seronegative persons. To determine whether human immunodeficiency virus (HIV) infection is associated with induration size among tuberculin reactors, a cross-sectional study of HIV-seropositive and -seronegative drug users was performed. Twenty- four of 160 (15%) HIV-seropositive and 68 of 284 (24%) HIV-seronegative patients had reactions to purified protein derivative (PPD) of ≤ 2 mm (OR = 0.56, 95% CI 0.32 to 0.96). However, the prevalence of tuberculin reactivity was equal among nonanergic subjects with and without HIV infection. Median induration size was similar among HIV-seropositive (20.5 mm) and - seronegative (17.5 mm) reactors. Thus, although HIV-seropositive patients were less likely, due to cutaneous anergy, to be PPD reactors, induration size was not associated with HIV infection among reactors. Although using a reduced cutpoint to determine suitability of chemoprophylaxis in HIV- seropositive persons may be prudent, the logical assumption that the loss of specificity this entails is accompanied by an increase in sensitivity for detecting Mycobacterium tuberculosis infection remains to be proved.

AB - Smaller tuberculin test induration sizes suggest eligibility for tuberculosis chemoprophylaxis in HIV-seropositive than in HIV-seronegative persons. To determine whether human immunodeficiency virus (HIV) infection is associated with induration size among tuberculin reactors, a cross-sectional study of HIV-seropositive and -seronegative drug users was performed. Twenty- four of 160 (15%) HIV-seropositive and 68 of 284 (24%) HIV-seronegative patients had reactions to purified protein derivative (PPD) of ≤ 2 mm (OR = 0.56, 95% CI 0.32 to 0.96). However, the prevalence of tuberculin reactivity was equal among nonanergic subjects with and without HIV infection. Median induration size was similar among HIV-seropositive (20.5 mm) and - seronegative (17.5 mm) reactors. Thus, although HIV-seropositive patients were less likely, due to cutaneous anergy, to be PPD reactors, induration size was not associated with HIV infection among reactors. Although using a reduced cutpoint to determine suitability of chemoprophylaxis in HIV- seropositive persons may be prudent, the logical assumption that the loss of specificity this entails is accompanied by an increase in sensitivity for detecting Mycobacterium tuberculosis infection remains to be proved.

UR - http://www.scopus.com/inward/record.url?scp=0029954927&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029954927&partnerID=8YFLogxK

M3 - Article

VL - 154

SP - 1029

EP - 1033

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 4 I

ER -